Press release from Companies

Publicerat: 2022-08-31 08:00:00

DanCann Pharma A/S: DanCann Pharma A/S publishes Q2-2022 report

COPENHAGEN, Denmark, 31 August 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter of 2022. The Q2-2022 report is available as an attached document to this press release and at

Group key figures Q2-2022:

KDKK 01/01/22
Net sales 2,037 0 771 0 874
Operating profit (EBIT) -9,304 -6,362 -5,759 -3,771 -14,509
Result per share (DKK) -0.03 -0.22 -0.02 -0.14 -0,52
Equity ratio 0.80 0.89 0.80 0.89 0,78

Number of shares on 31.03.22: 28.468.289 (28.468.289)
Result per share = Result for the period / weighted average number of shares
Equity ratio = Equity / Total assets

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

The next six months will be an epoch-making period for DanCann Pharma. Despite minor delays, we have never believed more that we are facing the company’s breakthrough. This is as a result of the fact that we expect to obtain our EU-GMP license, and for this admission under the Danish Medicines Agency’s Pilot Program for medical cannabis with our facility, Biotech Pharm1. And the same applies to our current application for our product application for the inclusion of a new product (extract of cannabis diluted in an oil) for the Danish market, which we also have high expectations for, will be a major contributor to the market. Most of all for the patients, but also in terms of generating a solid business for the company.

With that said, 2023 will be DanCann Pharma’s commercial breakthrough year, when we achieve proof-of-concept on several of our business legs, which is gratifying. And these commercial initiatives are already warmed up, due to a dialogue with companies from Denmark, Sweden, Germany, Poland, Israel and the UK, which we also expect to communicate more about during Q4-2022.

Financially, Q2-2022 was as expected in relation to our CannGros business, although this may seem below the last quarter in terms of revenue, which is due to overlaps (Q2 to Q3) between our deliveries to the wholesalers, for which we expect this to be balanced in Q3-2022.

Finally, we were recently able to communicate and disclose that we had finalized and disclosed our 2021 financial report for our acquisition, CannGros, which showed a prominent EBITDA of approx. DKK 1.7 million. Which we are very proud of, especially in an industry that is still as new and fragmented as ours.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Läs mer hos Cision
Läs mer om DanCann Pharma A/S